Patents by Inventor Bayard R. Huck

Bayard R. Huck has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for treating cancer using pyrimidine and pyridine compounds with BTK inhibitory activity
    Patent number: 11491153
    Abstract: The present invention provides methods of treating cancer using pyrimidine and pyridine compounds which are inhibitors of Bruton's tyrosine kinase (BTK).
    Type: Grant
    Filed: March 5, 2020
    Date of Patent: November 8, 2022
    Assignee: Merck Patent GmbH
    Inventors: Bayard R. Huck, Samantha M. Goodstal, Claude Gimmi-McKim
  • Methods for Treating Cancer Using Pyrimidine and Pyridine Compounds with BTK Inhibitory Activity
    Publication number: 20210244736
    Abstract: The present invention provides methods of treating cancer using pyrimidine and pyridine compounds which are inhibitors of Bruton's tyrosine kinase (BTK).
    Type: Application
    Filed: April 16, 2021
    Publication date: August 12, 2021
    Applicant: Merck Patent GmbH
    Inventors: Bayard R. HUCK, Samantha M. Goodstal, Claude Gimmi-McKim
  • Methods for Treating Cancer Using Pyrimidine and Pyridine Compounds with BTK Inhibitory Activity
    Publication number: 20200206224
    Abstract: The present invention provides methods of treating cancer using pyrimidine and pyridine compounds which are inhibitors of Bruton's tyrosine kinase (BTK).
    Type: Application
    Filed: March 5, 2020
    Publication date: July 2, 2020
    Inventors: Bayard R. HUCK, Samantha M. Goodstal, Claude Gimmi-McKim
  • Heterocyclic derivatives as modulators of kinase activity
    Patent number: 10287300
    Abstract: The invention provides novel imidazol-piperidinyl derivatives of the formula (I) in which R1, R2, W, X1, X2, X3, X4 and n have the meanings indicated in formula I, and their manufacture and use for the treatment of hyperproliferative diseases, such as cancer.
    Type: Grant
    Filed: November 20, 2017
    Date of Patent: May 14, 2019
    Assignee: Merck Patent GmbH
    Inventors: Ruoxi Lan, Bayard R. Huck, Xiaoling Chen, Yufang Xiao
  • Substituted pyrido[3,4-d]pyrimidines and pyrido[4,3-d]pyrimidines as p70S6K inhibitors
    Patent number: 10233160
    Abstract: Novel azaquinazoline carboxamide derivatives of formula (I) wherein W1, W2, W3, W4, R1, R2, R3 and m which are defined above, are p70S6K inhibitor, and can be employed, inter alia, for the treatment of hyperproliferative disorders.
    Type: Grant
    Filed: April 24, 2018
    Date of Patent: March 19, 2019
    Assignee: Merck Patent GmbH
    Inventors: Bayard R. Huck, Ruoxi Lan, Justin Potnick, Lizbeth Celeste DeSelm, Mark W. Cronin, Jr., Constantin Neagu, Xiaoling Chen, Roch Boivin, Theresa L. Johnson, Andreas Goutopoulos
  • Cyclic amine azaheterocyclic carboxamides
    Patent number: 10087166
    Abstract: The invention provides novel cyclic amine azaheterocyclic carboxamide according to Formula (I), Formula (II) and Formula (III) their manufacture and use for the treatment of hyperproliferative diseases, such as cancer.
    Type: Grant
    Filed: January 24, 2017
    Date of Patent: October 2, 2018
    Assignee: Merck Patent GmbH
    Inventors: Bayard R. Huck, Xiaoling Chen, Constantin Neagu, Reinaldo Jones, Yufang Xiao, Igor Mochalkin
  • Aminopyrimidine derivatives for use as modulators of kinase activity
    Patent number: 10080750
    Abstract: The invention provides novel heterocyclic amine compounds according to Formula (I) and their manufacture and use for the treatment of hyperproliferative diseases, such as cancer.
    Type: Grant
    Filed: April 18, 2017
    Date of Patent: September 25, 2018
    Assignee: Merck Patent GmbH
    Inventors: Ruoxi Lan, Bayard R. Huck, Xiaoling Chen, Lizbeth C. Deselm, Hui Qiu, Yufang Xiao, Constantin Neagu, Igor Mochalkin, Theresa L. Johnson
  • Heterocyclic carboxamides as modulators of kinase activity
    Patent number: 10080753
    Abstract: The invention provides novel heterocyclic carboxamide compounds according to Formula (I) their manufacture and use for the treatment of hyperproliferative diseases, such as cancer.
    Type: Grant
    Filed: August 3, 2016
    Date of Patent: September 25, 2018
    Assignee: Merck Patent GmbH
    Inventors: Bayard R. Huck, Xiaoling Chen, Yufang Xiao, Ruoxi Lan, Lizbeth Celeste De Selm, Constantin Neagu, Justin Potnick, Srinivasa R. Karra, Theresa L Johnson
  • AZAQUINAZOLINE CARBOXAMIDE DERIVATIVES
    Publication number: 20180237402
    Abstract: Novel azaquinazoline carboxamide derivatives of formula (I) wherein W1, W2, W3, W4, R1, R2, R3 and m which are defined above, are p70S6K inhibitor, and can be employed, inter alia, for the treatment of hyperproliferative disorders.
    Type: Application
    Filed: April 24, 2018
    Publication date: August 23, 2018
    Inventors: Bayard R. HUCK, Ruoxi LAN, Justin POTNICK, Lizbeth Celeste DESELM, Mark W. CRONIN, JR., Constantin NEAGU, Xiaoling CHEN, Roch BOIVIN, Theresa L. JOHNSON, Andreas GOUTOPOULOS
  • Substituted benzo[d][1,2,3]triazines as p70S6K inhibitors
    Patent number: 9981925
    Abstract: Novel azaquinazoline carboxamide derivatives of formula (I) wherein W1, W2, W3, W4, R1, R2, R3 and m which are defined above, are p70S6K inhibitor, and can be employed, inter alia, for the treatment of hyperproliferative disorders.
    Type: Grant
    Filed: August 3, 2016
    Date of Patent: May 29, 2018
    Assignee: Merck Patent GmbH
    Inventors: Bayard R. Huck, Ruoxi Lan, Justin Potnick, Lizbeth Celeste Deselm, Mark W. Cronin, Jr., Constantin Neagu, Xiaoling Chen, Roch Boivin, Theresa L. Johnson, Andreas Goutopoulos
  • Combinations of cancer therapeutics
    Patent number: 9980966
    Abstract: The invention relates to combinations of 4-[(S)-2-Azetidin-1-yl-1-(4-chloro-3-trifluoromethyl-phenyl)-ethylamino]-quinazoline-8-carboxylic acid amide and/or its physiologically acceptable salts and solvates, and an inhibitor of Her2, and the use of such combinations for the treatment of cancer.
    Type: Grant
    Filed: March 9, 2015
    Date of Patent: May 29, 2018
    Assignee: Merck Patent GmbH
    Inventors: Bayard R. Huck, Erik Wilker, Andreas Machl, Remigiusz Kaleta
  • C-ring modified tricyclic benzonaphthiridinone protein kinase inhibitors and use thereof
    Patent number: 9938268
    Abstract: Disclosed are C-ring modified tricyclic benzonaphthiridinone compounds and analogs thereof, pharmaceutical compositions comprising such compounds and processes for preparing the same. The compounds are useful in the treatment of diseases amenable to protein kinase signal transduction inhibition, regulation and/or modulation.
    Type: Grant
    Filed: December 2, 2009
    Date of Patent: April 10, 2018
    Assignee: Merck Patent GmbH
    Inventors: Yufang Xiao, Bayard R. Huck, Amanda E. Sutton, Thomas E. Richardson, Srinivasa R. Karra
  • Novel Heterocyclic Derivatives as Modulators of Kinase Activity
    Publication number: 20180072757
    Abstract: The invention provides novel imidazol-piperidinyl derivatives of the formula (I) in which R1, R2, W, X1, X2, X3, X4 and n have the meanings indicated in formula I, and their manufacture and use for the treatment of hyperproliferative diseases, such as cancer.
    Type: Application
    Filed: November 20, 2017
    Publication date: March 15, 2018
    Inventors: Ruoxi LAN, Bayard R. HUCK, Xiaoling CHEN, Yufang XIAO
  • Heterocycles as modulators of kinase activity
    Patent number: 9867826
    Abstract: The invention provides novel heterocyclic amines according to Formula (I) their manufacture and use for the treatment of hyperproliferative diseases, such as cancer.
    Type: Grant
    Filed: August 24, 2016
    Date of Patent: January 16, 2018
    Assignee: Merck Patent GmbH
    Inventors: Ruoxi Lan, Xiaoling Chen, Yufang Xiao, Bayard R. Huck, Andreas Goutopoulos
  • Heterocyclic derivatives as modulators of kinase activity
    Patent number: 9850255
    Abstract: The invention provides novel imidazol-piperidinyl derivatives of the formula (I) in which R1, R2, W, X1, X2, X3, X4 and n have the meanings indicated in formula I, and their manufacture and use for the treatment of hyperproliferative diseases, such as cancer.
    Type: Grant
    Filed: September 27, 2016
    Date of Patent: December 26, 2017
    Assignee: Merck Patent GmbH
    Inventors: Ruoxi Lan, Bayard R. Huck, Xiaoling Chen, Yufang Xiao
  • AMINOPYRIMIDINE DERIVATIVES FOR USE AS MODULATORS OF KINASE ACTIVITY
    Publication number: 20170217905
    Abstract: The invention provides novel heterocyclic amine compounds according to Formula (I) and their manufacture and use for the treatment of hyperproliferative diseases, such as cancer.
    Type: Application
    Filed: April 18, 2017
    Publication date: August 3, 2017
    Inventors: Ruoxi LAN, Bayard R. HUCK, Xiaoling CHEN, Lizbeth C. DESELM, Hui QIU, Yufang XIAO, Constantin NEAGU, Igor MOCHALKIN, Theresa L. JOHNSON
  • Aminopyrimidine derivatives for use as modulators of kinase activity
    Patent number: 9662330
    Abstract: The invention provides novel heterocyclic amine compounds according to Formula (I) and their manufacture and use for the treatment of hyperproliferative diseases, such as cancer.
    Type: Grant
    Filed: March 3, 2016
    Date of Patent: May 30, 2017
    Assignee: Merck Patent GmbH
    Inventors: Ruoxi Lan, Bayard R. Huck, Xiaoling Chen, Lizbeth C. Deselm, Hui Qiu, Yufang Xiao, Constantin Neagu, Igor Mochalkin, Theresa L. Johnson
  • Cyclic Amine Azaheterocyclic Carboxamides
    Publication number: 20170129877
    Abstract: The invention provides novel cyclic amine azaheterocyclic carboxamide according to Formula (I), Formula (II) and Formula (III) their manufacture and use for the treatment of hyperproliferative diseases, such as cancer.
    Type: Application
    Filed: January 24, 2017
    Publication date: May 11, 2017
    Inventors: Bayard R. HUCK, Xiaoling CHEN, Constantin NEAGU, Reinaldo JONES, Yufang XIAO, Igor MOCHALKIN
  • Methods for Treating Cancer Using Pyrimidine and Pyridine Compounds with BTK Inhibitory Activity
    Publication number: 20170119766
    Abstract: The present invention provides methods of treating cancer using pyrimidine and pyridine compounds which are inhibitors of Bruton's tyrosine kinase (BTK).
    Type: Application
    Filed: November 4, 2016
    Publication date: May 4, 2017
    Inventors: Bayard R. HUCK, Samantha M. GOODSTAL, Claude GIMMI-MCKIM
  • COMBINATIONS OF CANCER THERAPEUTICS
    Publication number: 20170100402
    Abstract: The invention relates to combinations of 4-[(S)-2-Azetidin-1-yl-1-(4-chloro-3-trifluoromethyl-phenyl)-ethylamino]-quinazoline-8-carboxylic acid amide and/or its physiologically acceptable salts and solvates, and an inhibitor of Her2, and the use of such combinations for the treatment of cancer.
    Type: Application
    Filed: March 9, 2015
    Publication date: April 13, 2017
    Inventors: Bayard R. HUCK, Erik WILKER, Andreas MACHL, Remigiusz KALETA